Aim immunotech reports fourth quarter and full year 2021 financial results and provides corporate update

- year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with ampligen® in multiple high-value indications
AIM Ratings Summary
AIM Quant Ranking